Gestational weight gain within the first 24 weeks is a significant prognostic factor for gestational diabetes mellitus (GDM), particularly in women who are already overweight or obese before becoming pregnancy, according to a retrospective cohort study.
Gestational weight gain within the first 24 weeks is a significant prognostic factor for gestational diabetes mellitus (GDM), particularly in women who already were overweight or obese before becoming pregnant, according to a retrospective cohort study.
The study examined the charts of 652 women, 163 who had developed GDM and 489 nondiabetic controls matched 3 to 1 by prepregnancy body mass index (BMI), age, race, and parity. Weight gain at 12 weeks' gestation for women in the GDM group was almost twice that of controls (4.0±8.2 lbs vs 2.8±6.5 lbs) and by 24 weeks, the GDM cohort had gained significantly more weight than controls (14.8±12.7 lbs vs 11.2±10.8 lbs; P<.001). Regardless of prepregnancy BMI, mean weight gain in the GDM group at 24 weeks was higher than that of controls.
Total weight gain during pregnancy differed significantly between controls and women with GDM who were overweight (P=.004) or obese (P=.008) before pregnancy. However, no significant difference in weight gain was seen between the GDM and control groups in women who were underweight or at normal weight before pregnancy.
The authors propose that because overweight and obese women have increased insulin resistance before conception, "the increase in gestational weight gain by 24 weeks may 'push them over the edge' toward GDM development."
As to the relationship between severity of GDM and 24-week weight gain, women whose diabetes was controlled with diet and exercise and those using insulin showed no difference in the 1-hour glucose challenge.
Gibson K, Waters TP, Catalano PM. Maternal weight gain in women who develop gestational diabetes mellitus. Obstet Gynecol. 2012;119(3):560-565.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More